BeOne Medicines (ONC) Other Non-Current Liabilities (2015 - 2026)

BeOne Medicines (ONC) has reported Other Non-Current Liabilities for 12 consecutive years, with $77.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 23.09% year-over-year to $77.6 million in Q2 2026; TTM through Jun 2026 was $77.6 million, a 23.09% increase from a year earlier, with the FY2025 full-year figure at $80.2 million, up 20.24% from the prior year.
• Other Non-Current Liabilities was $77.6 million for Q2 2026 at BeOne Medicines, down from $82.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $82.0 million in Q1 2026 and troughed at $42.0 million in Q3 2023.
• A 5-year average of $56.9 million and a median of $51.2 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities fell 17.28% in 2022 and soared 34.21% in 2025, its largest moves.
• Over 5 years, Other Non-Current Liabilities stood at $46.1 million in 2022, then rose by 10.23% to $50.8 million in 2023, then soared by 31.34% to $66.7 million in 2024, then gained by 20.24% to $80.2 million in 2025, then retreated by 3.24% to $77.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $77.6 million (Q2 2026), $82.0 million (Q1 2026), and $80.2 million (Q4 2025), per Business Quant data.